Glycofect cited by Salem et al in the Journal of Pharmaceutical Development and Technology
Title: "Poly(galactaramidoamine) is an efficient cationic polymeric non-viral vector with low cytotoxicity for transfecting human embryonic kidney (HEK293) and murine macrophage (RAW264.7) cells", published January 12, 2012
Techulon platform used for in vivo heart study
Techulon’s Platform Demonstrates Effective Non-Viral DNA Delivery for in vivo Cardiac Study. Techulon Glycopolymers Deliver NF-κB Decoy to Mitigate Injury from Cardiac Ischemia.
Techulon featured at VABIO Meeting December 8
Dr. Brett Malone is one of three biotech executives participating in a panel discussion at the VABIO meeting in Richmond, VA, on December 8.
Techulon Expands Coverage in Northern Virginia/Maryland Biotech Corridor
Local Sales and Technical Support for Glycofect Reagents to Government and University Laboratories
Glycofect featured in Trends in Biotechnology
Polymeric nanoparticle gene delivery using Poly(glycoamidoamine)s or PGAA's is reviewed in detail in Vol 29, Issue 9, September 2011 issue of Trends in Biotechnology.
Techulon at NIH Fall Research Festival October 27, 28
Visit us at Booth 152 on the Bethesda Campus of NIH.
BioConcept to distribute Glycofect in Europe
Techulon teams with BioConcept for European Distribution. "The innovative nature of Glycofect perfectly fits BioConcept's portfolio" -- Martin Howald, CEO/President of BioConcept.
Glycofect cited in Biomacromolecules journal
Published research studies stability of reagents used for siRNA delivery